SC144

SC144 is a first-in-class, orally active small-molecule inhibitor of glycoprotein 130 (gp130), a key signal transducer in the interleukin-6 (IL-6) signaling pathway. By binding to gp130, SC144 induces phosphorylation and deglycosylation of gp130, resulting in downregulation of surface gp130 and abrogation of gp130-associated STAT3 activation, leading to the inhibition of downstream oncogenic target genes. SC144 has demonstrated potent cytotoxicity in both drug-sensitive and drug-resistant cancer cell lines, and its oral administration delays tumor growth in mouse xenograft models of human ovarian cancer. The drug has also shown synergistic effects in combination with conventional cytotoxic agents such as 5-fluorouracil, oxaliplatin, and paclitaxel in preclinical models[1][2][3][4].

Other names

N'-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)pyrazine-2-carbohydrazide2-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl) 2-pyrazinecarboxylic acid hydrazideSC144 hydrochlorideSC-144 hydrochlorideSC 144 hydrochloride